Clinical Trial Update: Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and tolerability of Beclomethasone dipropionate plus Salbutamol fixed-dose inhalers (HFA vs CFC pMDI) over 12 weeks in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Beclomethasone dipropionate + Salbutamol fixed-dose combination inhaler

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Bronchial Asthma | Phase 3 | Status: COMPLETED